Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) EBIAT: 2019-2023

Historic EBIAT for ADC Therapeutics (ADCT) over the last 5 years, with Sep 2023 value amounting to -$46.7 million.

  • ADC Therapeutics' EBIAT rose 7.67% to -$46.7 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$36.2 million, marking a year-over-year increase of 72.47%. This contributed to the annual value of -$155,800 for FY2022, which is 32.27% up from last year.
  • Per ADC Therapeutics' latest filing, its EBIAT stood at -$46.7 million for Q3 2023, which was up 4.49% from -$48.9 million recorded in Q2 2023.
  • ADC Therapeutics' 5-year EBIAT high stood at $59.4 million for Q1 2023, and its period low was -$126.6 million during Q2 2020.
  • For the 3-year period, ADC Therapeutics' EBIAT averaged around -$33.1 million, with its median value being -$48.9 million (2023).
  • In the last 5 years, ADC Therapeutics' EBIAT crashed by 477,293.44% in 2020 and then spiked by 456.68% in 2023.
  • Over the past 5 years, ADC Therapeutics' EBIAT (Quarterly) stood at -$35,285 in 2019, then tumbled by 64,760.73% to -$20.3 million in 2020, then plummeted by 251.97% to -$34,381 in 2021, then increased by 29.74% to -$24,157 in 2022, then grew by 7.67% to -$46.7 million in 2023.
  • Its last three reported values are -$46.7 million in Q3 2023, -$48.9 million for Q2 2023, and $59.4 million during Q1 2023.